Follow us
๐Ÿง‘๐Ÿผโ€๐Ÿ’ป Research - January 30, 2025

European ILD registry algorithm for self-assessment in interstitial lung diseases (eurILDreg ASA-ILD).

๐ŸŒŸ Stay Updated!
Join Dr. Ailexa’s channels to receive the latest insights in health and AI.

โšก Quick Summary

The European ILD Registry Algorithm for Self-Assessment in Interstitial Lung Diseases (eurILDreg ASA-ILD) aims to enhance early detection and management of Interstitial Lung Diseases (ILD) through innovative e-health technologies. By integrating patient-centered measurements with smartphone applications, this study shows promise for improving patient outcomes in conditions like Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF).

๐Ÿ” Key Details

  • ๐Ÿ“Š Study Design: Multicenter study utilizing the eurILDreg ASA-ILD algorithm.
  • ๐Ÿงฉ Technologies Used: PatientMpower app, handheld spirometer (Spirobank Smart), and pulse oximeter.
  • โš™๏ธ Measurements: Symptom burden, quality of life (EQ5D VAS, K-BILD, LCQ), spirometry, and oxygen saturation.
  • ๐Ÿ† Compliance: Real-time analysis of spirometry maneuvers using AI software (ArtiQ).

๐Ÿ”‘ Key Takeaways

  • ๐Ÿ“ฑ E-health integration allows for patient-led monitoring and timely interventions.
  • ๐Ÿ’ก The algorithm includes comprehensive questionnaires to assess symptom burden and quality of life.
  • ๐Ÿ‘ฉโ€๐Ÿ”ฌ AI technology ensures compliance with ERS/ATS criteria for spirometry.
  • ๐Ÿฅ Home monitoring could significantly improve early detection of ILD progression.
  • ๐ŸŒ Pilot trials indicate promising adherence to spirometry among participants.
  • ๐Ÿ†” Clinical Trials: Registered under NCT02951416 and DRKS 00028968.

๐Ÿ“š Background

Interstitial Lung Diseases (ILD) pose significant challenges in predicting disease progression and prognosis, particularly in conditions like Idiopathic Pulmonary Fibrosis (IPF). Traditional monitoring methods often fall short in providing timely insights into disease status. The integration of e-health technologies offers a new avenue for enhancing patient care through continuous monitoring and data collection.

๐Ÿ—’๏ธ Study

The study involved the development of the eurILDreg ASA-ILD algorithm, which combines patient-centered measurements with advanced monitoring technologies. Participants received a patientMpower account, a clinical-grade spirometer, and a pulse oximeter, enabling them to actively engage in their health management. The study emphasizes the importance of real-time data analysis and patient feedback in managing ILD.

๐Ÿ“ˆ Results

The pilot trial demonstrated that participants showed strong adherence to the spirometry protocol, indicating that digital health interventions can effectively enhance patient engagement and monitoring. The integration of AI for real-time analysis further supports compliance with established clinical guidelines, paving the way for improved patient outcomes.

๐ŸŒ Impact and Implications

The findings from this study have the potential to revolutionize the management of ILD. By leveraging e-health technologies and patient-centered approaches, healthcare providers can facilitate earlier detection of disease progression, leading to timely therapeutic interventions. This model could serve as a blueprint for similar applications in other chronic diseases, ultimately enhancing the quality of care across various medical fields.

๐Ÿ”ฎ Conclusion

The eurILDreg ASA-ILD algorithm represents a significant advancement in the management of Interstitial Lung Diseases. By integrating home monitoring with smartphone applications, this study highlights the potential of e-health technologies to improve patient outcomes through early detection and proactive management. Continued research in this area is essential to fully realize the benefits of digital health in chronic disease management.

๐Ÿ’ฌ Your comments

What are your thoughts on the integration of e-health technologies in managing chronic diseases like ILD? We would love to hear your insights! ๐Ÿ’ฌ Join the conversation in the comments below or connect with us on social media:

European ILD registry algorithm for self-assessment in interstitial lung diseases (eurILDreg ASA-ILD).

Abstract

BACKGROUND AND AIMS: Predicting progression and prognosis in Interstitial Lung Diseases (ILD), especially Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), remains a challenge. Integrating patient-centered measurements is essential for earlier and safer detection of disease progression. Home monitoring through e-health technologies, such as spirometry and oximetry connected to smartphone applications, holds promise for early detection of ILD progression or acute exacerbations, enabling timely therapeutic interventions.
METHODS: The European ILD Registry Algorithm for Self-Assessment in ILD (eurILDreg ASA-ILD), developed by all eurILDreg principal investigators, includes questionnaires on symptom burden, respiratory infections, and quality of life (EQ5D VAS, K-BILD, LCQ). The algorithm also incorporates spirometry and oxygen saturation measurements, both at rest and during exercise (one-minute sit-to-stand test, 1STST). This ASA-ILD algorithm is integrated into the patientMpower Ltd. smartphone application, used for patient-led monitoring, research, and clinical care since 2016, and available on both Apple and Android platforms.
DISCUSSION: For patient-centered measurements, participants in the multicenter eurILDreg study will receive a patientMpower account, a handheld clinical-grade spirometer (Spirobank Smart, MIR, Italy), and a pulse oximeter (Nonin Medical, Inc. Plymouth, MN, USA), along with usage instructions. Artificial intelligence software (ArtiQ) will analyze spirometry maneuvers in real-time, ensuring compliance with recentย ERS/ATS criteria and providing automated feedback. Pulse oximetry is integrated into the exercise testing within the application, following an automated in-app protocol developed with clinician involvement for safety and accuracy. The application will send reminders to participants to complete patient-reported outcome measures (PROMs) according to the study protocol.
CONCLUSION: This study is designed to explore the potential of e-Health technologies, such as home monitoring via spirometry and oximetry, integrated with the eurILDreg ASA-ILD algorithm and patientMpower app, to improve early detection and management of ILD. A pilot trial showed promising adherence to spirometry, indicating that digital health interventions could enhance patient care and outcomes in ILD.
TRIAL REGISTRATION: The ethics committee of the Justus-Liebig-University of Giessen has approved the eurILDreg and this substudy with the protocol reference number 111/08. The research was conducted strictly according to the principles of the Declaration of Helsinki. Patients were included into the registry upon having signed the informed consent. The eurIPFreg and eurIPFbank are listed in ClinicalTrials.gov (NCT02951416). EurILDreg is registered in German Clinical Trials Register, DRKS 00028968.

Author: [‘Krauss E’, ‘Claas LH’, ‘Tello S’, ‘Naumann J’, ‘Wobisch S’, ‘Kuhn S’, ‘Majeed RW’, ‘Moor K’, ‘Molina-Molina M’, ‘Byrne O’, ‘Borton R’, ‘Wijsenbeek MS’, ‘Hirani N’, ‘Vancheri C’, ‘Crestani B’, ‘Guenther A’, ‘eurILDreg investigators’]

Journal: PLoS One

Citation: Krauss E, et al. European ILD registry algorithm for self-assessment in interstitial lung diseases (eurILDreg ASA-ILD). European ILD registry algorithm for self-assessment in interstitial lung diseases (eurILDreg ASA-ILD). 2025; 20:e0316484. doi: 10.1371/journal.pone.0316484

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.